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Trisomy 18: Is Amniocentesis Always Necessary?

ABSTRACT
OBJECTIVE: Our goal was to evaluate whether a normal ultrasound following a
positive triple marker serum screen reduces the risk of having a trisomy 18 fetus
to a level that is less than the procedure-related risk for amniocentesis. STUDY
DESIGN: A nonrandomized, non-concurrent cohort chart review was performed
o f all women who screened positive (risk > 1:250) for trisomy 18 by triple marker
serum testing through Spectrum Health Downtown Genetic Screening Program
from June 1996 through September 1999. O f the 13,618 serum samples screened,
158 were identified as being at an increased risk for trisomy 18. Pediatric
outcome was obtained through office documentation, review o f birth records, or
phone contact with the mother. RESULTS: Four cases o f trisomy 18 were
identified and all had abnormalities on ultrasound. CONCLUSION: The
presence o f normal ultrasound was not associated with significant increased risk
for trisomy 18. In this population, amniocentesis is not justified.
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CHAPTER ONE
INTRODUCTION
Background to Problem
Prenatal screening has become an important part o f the care o f pregnant
women in our society. The standard o f care today includes routine testing for
fetal anomalies in conjunction with regularly scheduled obstetric visits. Routine
testing means that the available screening is offered to the patient by her
practitioner as part o f antenatal care. The patient then has the option to either
accept or decline such testing after being informed o f its risks and benefits.'
Prenatal screening allows parents to make informed decisions regarding the care
o f their baby.'
One specific use o f prenatal screening is the detection o f certain
chromosomal abnormalities such as trisomy 21 and trisomy 18. The current
methods used for determining the fetal anomalies associated with trisomy 21 and
trisomy 18 are: the maternal triple marker serum screen; ultrasonography; and
amniocentesis. The triple marker screen is offered to the pregnant woman as a
first option in screening for chromosomal aberrations. This screen in typically
offered between 15 and 22 weeks gestation. The second trimester triple marker
serum screen consists of: maternal P-human chorionic gonadotropin (P-hCG);
unconjugated estriol; and alpha fetoprotein (AFP). These markers have been
shown to be o f value in evaluating pregnancies at risk for various anomalies and

aneuploidies.^ Second trimester maternal levels o f AFP, unconjugated estriol,
and P-hCG are all at lower than normal levels in the presence o f trisomy 18, with
estriol being the most sensitive/ ^^ Triple marker serum screen testing has allowed
earlier detection o f potential defects than routine sonographic screening alone;
however, the triple screen test has also led to the identification o f a population of
patients that require genetic counseling and may require additional testing.
Ultrasound is the other non-invasive test used to detect chromosomal
abnormalities. This method o f surveying the fetus allows for information to be
obtained about the fetus and its environment.^ Specific anomalies can be viewed
on ultrasound that correlate highly with trisomy 21 and trisomy 18. The
incorporation o f ultrasound as a prenatal screening tool may be related to
improved perinatal and maternal outcome while avoiding the use o f invasive
procedures.’
Amniocentesis is the “gold standard” test in that it provides the definitive
diagnosis o f chromosomal aberrations.W om en who screen positive on a triple
test are typically offered chromosomal analysis with amniocentesis; however, this
test is an invasive procedure involving needle aspiration o f amniotic fluid and
cells." Amniocentesis is a procedure which is associated with complications for
the mother and her unborn fetus. Although the risk o f procedure-related
pregnancy loss is small, it is important for women undergoing this invasive
procedure to be informed o f such risks."

Trisomy 18 is a chromosomal abnormality that results in an extra
chromosome 18, causing a condition that is eventually lethal. The second
trimester incidence of trisomy 18 is approximately 1:2400 with a birth incidence
o f approximately 1:8000. The difference in the incidence rates is due to a 70%
fetal loss in the third trimester.^ Even after successful delivery, the prognosis
remains poor with at most a 10% survival rate up to one year.'^ This poor
prognosis makes diagnosis o f trisomy 18 important. Prenatal diagnosis would
provide the patient with a variety o f options including termination o f the
pregnancy, avoidance o f cesarean section, delivery locally with conservative
management, or emotional preparation for the delivery o f an abnormal neonate.'^
Data suggests that ultrasound following a positive triple marker screen
may provide guidance regarding the decision for definitive diagnosis with
amniocentesis in trisomy 21. Very recent data suggests that this may also be
possible for trisomy 18; however, studies published thus far concerning abnormal
triple screen have indicated the need for further evaluation with ultrasound or
ultrasound in combination with amniocentesis. This project will focus on the
utilization o f non-invasive prenatal screening to guide the decision for
amniocentesis for the purpose o f trisomy 18 detection.
Statement o f Problem
Research involving the prenatal diagnosis o f trisomy 18, without the use
o f amniocentesis, has been mostly inconclusive. Research exists on the
sonographic findings o f trisomy 18 and the parameters o f triple marker serum
screen, but little research has been conducted on the risk o f trisomy 18 based on

the combination o f these two antenatal tests. The combination o f ultrasound with
the biochemical markers is thought to yield a more sensitive predictive risk o f
fetal anomalies for women to base their prenatal decisions on.'^ Many women in
institutions throughout West Michigan are currently being offered triple marker
screening as part o f routine prenatal care. Women who are offered the option to
undergo maternal serum screening would be counseled on the significance o f the
results so that they are able to make informed decisions on further testing. Those
women who screen positive for trisomy 18, which is defined as a risk greater than
1:250, typically undergo further evaluation by ultrasonography. The question
which arises is how to counsel women on the likelihood o f trisomy 18 based on
ultrasound findings and abnormal triple screen. Specifically, does a normal
ultrasound further reduce the risk o f trisomy 18 and possibly obviate the need for
invasive testing by amniocentesis?
Purpose
The piupose of our study is to reduce invasive prenatal testing with its
associated perinatal risks. Kellner et al. report a potential loss o f 3 to 4 unaffected
fetuses out o f a group o f 700 patients as a result o f amniocentesis. '^ Older women
who have delayed childbearing and those that have had previous treatment for
infertility may not consider the risk o f amniocentesis to be low enough to justify
detecting the chromosomal abnormality.* We hope to reduce the amount of
invasive testing by determining whether a normal ultrasound following an
abnormal triple screen reduces the risk o f trisomy 18 to the point where
amniocentesis would carry a greater risk than that o f the chromosomal

abnormality. This information will contribute to a step-wise approach in
evaluating pregnant women that have screened positive for trisomy 18.
Significance o f the Problem
Prenatal diagnosis o f chromosomal abnormalities is important in that it
allows the practitioner to provide the patient with options. In this study, we are
trying to determine the probability o f the fetus having trisomy 18 with less
invasive and less risky procedures. Unfortunately, the majority o f genetic
amniocenteses are performed on normal fetuses.'^ The average pregnancy loss due
to genetic amniocentesis is roughly 1 in 270. Therefore, it is important to
determine techniques that define a more select group o f candidates for invasive
prenatal testing to decrease fetal losses due to amniocentesis.'^ By reducing
invasive procedures, there is a decreased risk to the fetus as well as a reduction in
unnecessary health care expenditure. Therefore, we hope to decrease the size o f
the population that will need further invasive testing for definitive diagnosis of
trisomy 18. As health care providers, education is a vital component in delivering
quality patient care. This research will contribute information for providers to use
in counseling patients who have an abnormal triple screen.
Further research is needed in detecting trisomy 18 with triple marker
screening and ultrasound. Yankowitz et al. conducted a recent study to evaluate
the efficacy o f prenatal serum screening for trisomy 18. The investigators
concluded that combining serum screening with detailed ultrasound might further
define the population that would most benefit fi-om invasive testing.^ We hope to
extend the validity o f the study with this objective in mind by investigating a new

sample population in a different geographical area. We will evaluate a population
o f patients at an increased risk for trisomy 18 based on mid-second trimester triple
serum screening and review the patients’ ultrasound findings. The expected
outcome o f this study is to determine how risk may be assessed on the basis o f
ultrasound findings.

CHAPTER TWO
REVIEW OF LITERATURE
Trisomy 18
Trisomy 18 is the second most common autosomal trisomy with a birth
incidence between 1:7000 and 1:8000.‘^ ‘* The low birth incidence o f trisomy 18
is directly related to the increased number (70%) o f spontaneous abortions in the
third trimester o f life.'* This relatively lethal condition is most often caused by a
meiotic non-disjunction o f chromosome 18.” Similar to trisomy 21, the birth
incidence o f trisomy 18 increases with maternal age.'* Long term survival is rare
in that approximately 50% o f trisomie 18 fetuses will die within 10 days to 2
months of birth and over 90% by 100 days.^ '’ An infant with trisomy 18 will
rarely survive beyond one year since this condition is associated with multiple
structural abnormalities and extreme growth retardation.'® '* These structural
malformations can be seen and detected on ultrasonography.
Trisomy 18 remained an unrecognized entity until 1960 when the first full
report o f a child with trisomy 18 syndrome was described by Edwards, Hamden,
Cameron, Crosse, and Wolff.^' At the same time, Patau, Smith, Therman, Inhorm,
and Wagner reported the discovery o f two infants with a similar syndrome;
however, the researchers were only able to identify the extra chromosome as
being from the E group which consists o f chromosome numbers 16 to 18. In an
addendum, they mentioned 4 more cases and were able to identify the

chromosome as number 18.^ Subsequent reports o f similarly affected infants soon
followed. Patau, Therman, Smith, and DeMars compared the abnormalities o f the
two affected fetuses against the infant Edwards et al. had described and concluded
that all o f these cases represented the same disorder caused by an extra
chromosome number 18.^ The most prominent clinical abnormalities noted in
these trisomy 18 infants were: mental retardation with moderate hypertonicity;
low-set malformed ears; small mandible; flexion o f the fingers with the index
finger overlapping the third; and severe failure to thrive. The flexion o f the fingers
with the index overlapping the third digit was significant for diagnosis o f the
syndrome because it is such an imusual anomaly.^ The phenotypic expression of
trisomy 18 was found to vary with a wide range o f anomalies. Each one,
however, was not present in every patient.^
Another early study in 1962 reported on 6 definite cases and 1 possible
case o f trisomy 18.^ These cases were confirmed by cytological preparation and
analysis. The most fi*equent anomalies noted of these seven trisomy 18 cases
were: apparent mental retardation; failure to thrive; flexion and deviation o f the
fingers; low-set and malformed ears; micrognathia; defectively ossified and short
sternum; diaphragmatic hernia or eventration; hypertonia; limited hip abduction;
dorsiflexed and short great toe; malformation of the heart; malformation o f the
kidney; prominent occiput; diastasis recti abdominus or peri-umbilical hernia;
rocker-bottom feet or equinovarus; and limpness and hypotonia at birth.^ The
investigators concluded that the trisomy 18 syndrome was a well-defined entity.^

While there are many published descriptions o f trisomy 18, there is little
information about the cause o f death and the length o f survival. Embleton et al.
explored the cause o f death because many clinicians blamed the rapid demise o f
the trisomie fetus on congenital heart disease.^^ The researchers conducted a
retrospective study for all cases o f trisomy IS between 1986 and 1992. O f the
282,583 births during that time, 66 fetuses at 18 weeks gestation with trisomy 18
were identified. O f the 66 trisomie pregnancies, 23 were terminated, 6
spontaneously aborted, 3 were stillborn, and 34 were bom living. The observed
prevalence was 1 in 4274 at 18 weeks gestation. The prevalence decreases to 1 in
8333 live births at the time o f delivery.*^ Trisomy 18 was diagnosed antenatally in
28 cases. O f these 28 cases, only two were carried to term. The mode o f delivery
in 64% o f the cases was by cesarean section. In this group, only one case had
been diagnosed antenatally and cesarean section was performed to save the
unaffected twin o f the trisomie baby. Thirteen o f these cesarean sections were
performed due to fetal complications such as fetal distress and cord prolapse.
Prior diagnosis might have allowed for vaginal delivery. Twenty-one infants were
determined to have cardiac malformations. Nine babies died within a few hours
following birth. Only three cases were presumed to expire from cardiac
abnormalities. None o f the infants who lived beyond two days died o f cardiac
complications; therefore, cardiac surgery would not have affected fetal outcome.
The most common mode o f death was found to be central apnea, and this was the
cause o f death in 10 cases.^^

Prenatal Screening
Screening programs for pregnant women have caused much debate since
the advent o f tests such as amniocentesis and chorionic villus sampling. More
specifically, there has been continued debate about which populations should
undergo such testing because o f health care cost and the risks associated with
them. Previously, prenatal screening was only offered to women over 35 because
of the invasive nature o f the tests. Without a non-invasive screening test, fetal
loss due to testing and the cost of the procedure limited the efficacy o f prenatal
diagnosis. Use o f such screening programs as ultrasound and triple marker
screening have raised many questions about counseling and testing protocol.
Screening for chromosomal abnormalities has been traditionally offered to
women considered to be at risk because o f advanced age or other risk factors.
Almost all women presently are offered some form o f prenatal screening which
may include ultrasound, triple marker screen, and amniocentesis. The prenatal
screening tools available to women during pregnancy have continued to improve
and multiply throughout the past ten years.* With new technology and availability
o f prenatal screening, some researchers have become concerned about the
specificity and sensitivity o f the tests. For example, Doman et al. expressed
concern about the extension o f these tests into populations which have not been
researched and whether this would result in increasing numbers o f false positive
results and more unnecessary invasive testing. Doman et al. felt prenatal
diagnosis through early screening would allow parents to make informed
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decisions. They foresaw a need for uniformity in the way the tests are offered and
interpreted in order to decrease false positive results.^
Increased availability o f procedures to detect fetal abnormalities prenatally
has caused some researchers to question the impact caused by the technology. A
study done by Forrester et al. examined the effect o f prenatal diagnosis and
elective termination on the prevalence o f certain birth defects.^ They included
electively terminated cases into calculations o f birth prevalence rates and found
that this increased the rates by more than 50% for 5 o f the 10 birth defects studied.
Elective terminations had the most effect on the rates o f neural tube defects
(NTD) and chromosomal abnormalities. By taking into consideration the number
o f elected terminations, there was a 58% increase in trisomy 13 rates and 100%
increase in trisomy 18 rates.^ Birth defects such as anencephaly, trisomy 18, and
trisomy 21 that result in a poor prognosis or substantial disability were more
likely to end in elective terminations after prenatal diagnosis.
There is often controversy over the need to have a screening program for
trisomy 18 due to its low birth prevalence and the high mortality rate for affected
infants. Prenatal diagnosis o f trisomy 18 allows the parents to prepare themselves
for the birth o f abnormal child with a poor chance for survival. On a psychosocial
level this information can prove to be valuable to parents to allow for adequate
grieving and decision making. Medical concerns such as a high rate o f cesarean
section in association with trisomy 18, support the need for antenatal
identification o f these infants as well. When trisomy 18 remains undiagnosed
prenatally, there is a high rate o f cesarean section in these mothers due to the
II

frequent association between trisomy 18 and intrauterine growth retardation
Diagnosis o f fetal distress is twice as common in infants with
growth retardation. Cases in which primary cesarean section was performed for
fetal distress resulted in an unjustified risk to the mother when ultimate fetal
outcome is unfavorable either way.“
Triple Marker Screening
As stated previously, invasive prenatal tests cannot be offered to every
pregnant woman because o f the cost o f such procedures and the associated
complications. A number o f non-invasive screening tests aimed at selecting
higher risk pregnancies have been developed but are continuously in need o f
improvement. Screening for chromosomal abnormalities includes serum marker
screening, advanced maternal age, and ultrasound findings. The maternal triple
marker serum screen is the most widely used prenatal screen for chromosomal
abnormalities. This screen consists o f three biochemical markers: P-human
chorionic gonadotropin (P-hCG); unconjugated estriol (uE3); and alpha
fetoprotein (AFP). Each o f these biochemical markers is produced by the fetus or
the placenta and passes into maternal circulation. Human chorionic gonadotropin
is produced by the placenta and is a glycoprotein similar to luteinizing hormone
(LH), follicle stimulating hormone (FSH), and thyroid stimulating hormone
(TSH). The hCG consists o f an alpha-subunit and a beta-subunit. The levels o f
P-hCG follow a specific pattern throughout the gestation o f a fetus. This pattern
begins with implantation to 8 weeks gestation when the levels begin rise. The
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concentration plateaus from 8 to 12 weeks gestation, decreases from 12 to 18
weeks, and plateaus again until term.~^ Unconjugated estriol is formed from
dehydroepiandosterone sulfate (DHEAS) which is converted in the fetal liver to
16-alpha-OH-DHEAS and then becomes unconjugated estriol in the placenta.
AFP is produced primarily in the fetal liver as well as the yolk sac and the
gastrointestinal t r a c t . F e t a l plasma levels o f AFP peak between 10 and 13
weeks and then decrease until term.”
Maternal serum screening is a blood test that is typically offered between
16 and 21 weeks gestation. The biochemical markers are calculated and reported
in Multiples o f the Median (MoM). These serum markers are initially measured
in mass units and then converted to MoMs based upon proven normal pregnancies
at the same gestational age. By reporting the values in this way, the values can
be adjusted for biological variables that are known to affect the maternal serum
levels such as maternal weight, insulin-dependent diabetes, and race.^*’^° In
screening specifically for trisomy 18, the levels for all three biochemical markers
are lower than normal values for gestation age.
Merkatz et al. were the first to observe a decreased maternal biochemical
marker in a trisomie 18 fetus.” Their research was prompted by an index case o f
“undetectable” maternal serum AFP in a 28 year-old primigravid women at 16
weeks that resulted in the birth o f a trisomy 18 infant. During the pregnancy the
mother had inquired about amniocentesis but was told the procedure was not
recommended due to her young age; however, she did undergo routine AFP
screening and had two results that were described as “below sensitivity” o f the
13

test. At the time, the literature revealed that the significance o f low midtrimester
maternal AFP levels was unclear but seemed to be correlated with higher than
estimated rates o f spontaneous abortion. This observation incited Merkatz et al.
to further research this relationship.”
Merkatz et al. used three different populations in a retrospective study o f
prenatally diagnosed chromosomal abnormalities.” The first group was evaluated
for maternal age distribution. The researchers found that among all trisomy 18
and trisomy 21 births, 68% occurred in women who were 34 years o f age or
younger. Due to the fact that almost three-fourths o f trisomie affected births
occur in women who are younger than the standard cutoff o f age 35 and due to the
expense of prenatal diagnosis, Merkatz et al. suggested the need for a screening
tool to identify a high-risk subset o f pregnant women. The second and third
populations evaluated the use o f AFP as a screening tool. They concluded that
using low AFP values as a criterion to do further prenatal testing for diagnosis
would reduce the number o f amniocenteses to approximately one chromosomal
abnormalities for every 35 to 40 performed. This ratio is compared to 1 to 2
chromosomal abnormalities for every 100 amniocenteses performed when
maternal age is used as the criterion.”
The earliest screens measuring biochemical analytes were first performed
using AFP exclusively to screen for Down’s syndrome. With continuing research,
p-hCG and uE3 were used in addition to AFP because o f an increased detection
rate o f aneuploidy. Kellner et al. found using all three markers together in
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correlation with maternal age increased the detection rate o f chromosomal
abnormalities versus AFP and hCG without estriol.'^ The results of the study also
indicate a higher detection rate by using the three serum markers with other
chromosomal abnormalities without a change in the false positive rate.''*
With progression in research on the accuracy o f the triple marker
screening test for detecting chromosomal abnormalities, Kellner et al. raised the
question whether amniocentesis needs to be offered to a more defined
population.'■* Using the triple screen in women age 35 and greater in the study
group, a total o f 700 women were spared from undergoing amniocentesis, while 4
out o f 5 cases o f trisomy 21 were detected by offering amniocentesis to only 186
women. Statistically, the loss of 3 to 4 unaffected fetuses would be spared as
well. On the other hand, offering amniocentesis to women less than 35 years o f
age resulted in an increase detection o f abnormalities. The researchers also noted
that the ultrasound was able to detect an additional 2 cases o f trisomy 21 and
suggested that it may be a useful additional screening tool. In conclusion, the
researchers found the triple screen in correlation with maternal age has increased
detection o f chromosomal abnormalities, allowing for another option for older
women who are usually candidates for amniocentesis.
Maternal serum screening for trisomy 18 was initiated as an extension of
second-trimester maternal blood screening for Down’s syndrome. In 1992
Kellner et al. began screening for trisomy 18 in addition to their trisomy 21
screening study. The study population included 8,649 women o f the original
10,605 who were initially screened for trisomy 21. A test was considered screen
15

positive for trisomy 18 if the three biochemical markers were low. The screen
positive test was determined with the following values: AFP < 0.75 MoM, uE3 <
0.60 MoM, and p-hCG < 0.55 MoM. O f the 8649 serum samples tested, 23
women screened positive for trisomy 18. Twenty o f these women elected to
undergo amniocentesis. Two cases were detected by amniocentesis resulting in 1
case per 11.5 amniocenteses. There was 1 case that was missed by the screening
and one fetal death in which trisomy 18 could not be ruled out."
Leporrier et al. examined 33 cases o f known trisomy 18 pregnancies in
order to evaluate two maternal serum biochemical markers, specifically
unconjugated estriol and human chorionic gonadotropin.'^ The levels for both u£3
and hCG were found to be significantly lower as compared to unaffected
pregnancies. The researchers point out the advantages to using these biochemical
markers as routine screening are a reduction in the number o f amniocenteses
performed, as well as earlier detection o f the disease.'^
W ith continuing research on the detection o f trisomy 18, the triple serum
screen was found to be a better screen than AFP alone or AFP and P-hCG in
combination. With the addition o f estriol, 60% o f pregnancies with trisomy 18
would be detected at the same false positive rate o f 0.2%. The detection rate
doubles in comparison to using only AFP and P-hCG.^ In 1993, Barkai et al.
concurred with previous studies that the triple marker screen could be modified to
detect trisomy 18 as well as trisomy 2 1 The difference between the two
syndromes is a decreased level o f P-hCG in trisomy 18 in contrast with an
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increased level in trisomy 21. Depending on the risk cut-off rate o f either 1:10 or
1:1 GO, multiple marker screening could potentially detect 67-80% o f trisomy 18
cases, with a false positive rate o f 0.3-0 6% respectively
As prenatal screening programs routinely began using the triple marker
screen for the detection o f trisomy 18, research was directed towards evaluating
the efficacy o f the triple marker screen. A prospective intervention trial to
evaluate the performance o f a screening protocol for trisomy 18 in routine practice
was carried out by Palomaki et al. in 1991.^' A total o f 92 o f the 19,491 singleton
pregnancies studied were identified as high risk, meaning they were screen
positive for trisomy 18. The following serum biochemical marker levels were
defined as a positive screen or high risk pregnancy: AFP < 0.75 MoM, uE3 <
0.60 MoM, and hCG < 0.55 MoM. Ninety-six percent o f the women elected
further karyotyping by amniocentesis. Six o f the 92 screen positive women
actually had fetuses with trisomy 18, making the odds o f having an affected fetus
1:14. The results indicate an estimated detection rate o f 85% using this screening
protocol. Thus, the method utilizing the three serum markers compared to the
alternative method o f using p-hCG alone as a screening tool shows an improved
detection rate and a decreased false positive rate.^'
A study by Yankowitz et al. was done to determine the efficacy o f the
prenatal serum screen for trisomy 18.*^ Maternal serum samples were drawn
between 15 and 20 weeks gestation. Those screens considered positive for
trisomy 18 had maternal serum AFP < 0.75 MOM, estriol < 0.60 MOM, and p-
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hCG < 0.55 MOM. Serum AFP values were corrected for maternal weight, race,
and Type 1 diabetes mellitus. Estriol and p~hCG were corrected for maternal
weight. Fetal ultrasound evaluation included biometric parameters, assessment of
fetal structure, and amniotic fluid. Patient follow-up was obtained through
evaluation o f karyotype if amniocentesis was performed, birth certificate data, or
telephone contact with the patient or physician. During the study 40,762 women
were screened with 175 being screen positive for trisomy 18. The results
indicated that eight fetuses out of the 175 that had a positive triple screen were
actually diagnosed with trisomy 18. One hundred twenty-one women o f the 175
that had a positive screen elected to undergo amniocentesis, which resulted in the
identification o f only one trisomie 18 fetus. O f the 8 fetuses who were afflicted
with trisomy 18, only 3 mothers elected to undergo ultrasound after having
screened positive for the triple marker serum screen. Remarkably, all three o f the
fetuses showed abnormalities on ultrasound.^
Yankowitz et al. argued that combining serum screening with genetic
ultrasound may improve the predictive value o f those who screen positive for
trisomy 18. This would be accomplished by targeting a more precise group at a
higher risk o f trisomy 18 for amniocentesis. By combining ultrasound with the
triple m arker screen, the researchers theorized that the number o f women
undergoing amniocentesis could have been reduced from 121 to 27. Yankowitz et
al. go on to suggest that all women who screen positive should first undergo
ultrasound and then be counseled for further genetic testing based on the
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calculated risk o f trisomy 18. Normal ultrasound results would potentially
eliminate 80% o f the risk of trisomy 18 *
Ultrasonographic Findings
Ultrasound is a diagnostic tool that is used by physicians to assist them in
detection o f multiple gestations and fetal abnormalities. In women with
unreliable dates o f last menses, an estimation o f gestational age can also be
determined through the use o f ultrasound. Real time ultrasound using high
frequency sound waves to produce a two-dimensional image gives the physician
the capability to survey both structural and functional characteristics o f the fetus,
as well as the location and morphology o f the placenta. A study performed by
Magriples et al. evaluated the accuracy o f routine ultrasound screening for fetal
anatomy and anomalies.^^ The investigators found routine ultrasound screening to
be extremely sensitive in the detection o f fetal anomalies in women screened
before 26 weeks gestation. Sensitivity and specificity o f ultrasound screening in
this study were found to be 71.4% and 99.4% respectively.^^ Findings are
significant due to the fact that a majority o f fetal malformations occur in pregnant
women having no known risk factors.
Ultrasound has made it possible to visualize structural malformations
associated with chromosomal abnormalities and neural tube defects. There has
been ongoing research on the use o f ultrasound as a routine prenatal screening for
specific chromosomal abnormalities such as Down’s syndrome and trisomy 18.
The motivation to incorporate ultrasound as a routine prenatal screening is to
improve perinatal and maternal outcome while decreasing the use o f invasive
19

testing. Recent research has been able to describe sonographically detectable
abnormalities associated with specific chromosomal anomalies.
Benacerraf et al. conducted a series o f studies focusing on the accuracy
and limitations o f ultrasound in the detection o f trisomy 18. This resulted in their
development o f a scoring system for sonograpic features. In one o f their early
studies, Benacerraf et al. examined the accuracy and limitations o f prenatal
ultrasound in identifying fetuses with trisomies 13 and 18.^^ Patients scanned
between January 1, 1984 and February 1, 1987 who had cytogentic diagnoses o f
trisomy 13 or 18 were included in the study. All ultrasounds were done between
15 and 40 weeks gestation without any knowledge o f karyotype. There were 15
cases o f trisomy 18. Twelve o f the 15 cases had abnormalities detected by
ultrasound. Eleven o f these fetuses had abnormalities o f the hands or feet, three
had diaphragmatic hernia, and one had micrognathia. O f the twelve cases with
abnormalities detected by ultrasound, six were scanned between 15 and 22 weeks,
one at 25 weeks and 5 between 31 and 40 weeks. All three fetuses who did not
have sonographic abnormalities were seen between 16 and 17 weeks.
Sonographic identification for trisomy 18 in this study was approximately 80% ."
With this study Benacerraf et al. were unable to conclude whether ultrasoimd is
predictive in diagnosing trisomies due to the small number o f cases.
In a following study, Benacerref et al. further examined abnormalities seen
on ultrasound and derived a scoring system to be used to detect fetuses at
increased risk for aneuploidy." The system was scored as follows; nuchal fold 2,
major defect 2, short femur 1, short humerus 1, and pyelectasis 1. A score o f 2
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would mean increased risk o f anueploidy. Using this system there is a potential
for identifying as many as 80% o f trisomy 21 fetuses, 100% o f trisomy 13 and 18
fetuses while keeping a low false-positive rate o f 4.4%.^
In a 1994 follow-up study, Benacerref et al. evaluated the ability to
determine autosomal trisomy fetuses by using their previously determined scoring
system for sonographic features.^^ They selected a new population that was
scanned before karyotyping to avoid overlap with their earlier study. The two
new criteria added to the scoring system were hyperechoic bowel = 1 and choroid
plexus cysts = 1. The amniocentesis findings identified 60 trisomie fetuses with
13 trisomy 18 fetuses. These were compared to 106 control fetuses that
underwent scanning and amniocentesis at approximately the same time. A score
o f two was used as an indication o f increased risk o f anueploidy warranting
karotyping. This score o f 2 identified 11 o f the 13 trisomy 18 fetuses or 85%.
The 2 fetuses with trisomy 18 that were not identified were scanned at 15 weeks
or earlier which limits the structural survey. According to Benacerraf et al., the
optimal time to perform sonographic evaluation is 18 weeks since the fetal heart
can be evaluated better. If only fetuses that were scanned at 18 weeks or older
were included then 11 of 11 or 100% o f trisomy 18 fetuses would have been
detected. Benacerraf et al. suggest that the scoring system with triple marker
screening may allow for a refined prediction o f risk o f aneuploidy and thereby
performing fewer amniocentesis that have a higher sensitivity and positive
predictive value in detecting aneuploidy
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A case review o f the ultrasonographic findings in 47 fetuses with trisomy
18 was carried out by Nyberg et al. in 1992.^* Twenty-nine o f the 47 total fetuses
were examined between 14 and 24 weeks. The other 18 fetuses were scanned
after 24 weeks. Abnormalities excluding choroid plexus cysts were identified in
83% o f the fetuses. The abnormalities detected in this study included the
following: intrauterine growth retardation (51%); cardiac defects (38%); cystic
hygromas, lymphedema or nuchal thickening (19%); prominent or enlarged
cistema magna (19%); meningomyelocele (17%); omphalocele (21%); renal
abnormalities (15%); single umbilical artery (13%); clubbed or rocker bottom feet
(21%); and clenched hands (19%).^^ Cardiac defects, enlarged cistema magna, and
lUGR were more likely to be detected in the third trimester in contrast with cystic
hygromas. Clubbed feet or persistently clenched hands were the most common
abnormalities o f the extremities.^^ This study demonstrates the use o f ultrasound
in detecting trisomy 18 in reporting ultrasonographic abnormalities associated
with the syndrome. This further points to the efficacy o f using ultrasound to
evaluate patients with an increased risk for trisomy 18 based on serum
biochemical markers.
While previous studies have reported an 80 to 85% ability to detect
abnormalities specific to trisomy 18, the ultrasoimds have inconsistently been
performed at various gestational ages between 12 and 40 weeks.^^ Most pregnant
women undergo a screening ultrasonogram early in the second trimester. A study
by Shields et al. focused on the prenatal detection o f ultrasonographic
abnormalities in fetuses with trisomy 18 during the early second trimester.^’ Their
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patient population included all patients that were referred to the University of
Washington Prenatal Diagnosis Center between January 1, 1987 to June 30,1996.
The fetuses o f these women were between 14 and 22 weeks gestation with a fetal
karotype indicating trisomy 18. Thirty-five cases o f trisomy 18 were identified.
The mean time o f evaluation for the fetuses was 17.2 ± 2.0 weeks. The ultrasound
evaluation included standard biometry measurements o f biparietal diameter, head
circumference, abdominal circumference, and femur length as well as fetal
anatomic evaluation o f the cerebral ventricles, posterior fossa, spine, fourchamber view o f the heart, stomach, kidneys, and bladder. O f the 35 fetuses
studied, 30 (86%) had at least one sonographic abnormality detected. The most
common abnormality detected was persistent abnormal positioning o f fetal fingers
or a clenched fist. Abnormalities in regard to fetal hands were found in 18 cases
with 16 having positional abnormalities o f the fingers. Abnormal positioning of
the hand was seen in almost 90% o f the fetuses whose hands were evaluated.
Shields et al. comment that while careful documentation o f hands would not
identify all abnormal fetuses, it would take little additional time to obtain during a
routine scan. This finding seems to have a high predictive value in detecting
chromosomally abnormal fetuses. O f the 5 fetuses that had anatomically normal
ultrasounds, there was only one case in which the hands were noted to be
sonographically normal. The next most common finding was choroid plexus cyst.
Fifteen patients or 43% were noted to have this abnormality. In 5 o f these 15
cases, a choroid plexus cyst was the only abnormality noted. Other anomalies
found included: abnormal cranial shape such as the lemon-shaped and the classic
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strawberry-shaped heads; two-vessel umbilical cord; cardiac defects; intrauterine
growth restriction; omphalocele; neural tube defects; and cystic hygroma or
lymphangiectasia. This study notes that a majority o f fetuses with trisomy 18 will
have ultrasonographic abnormalities that can be detected between 14 and 22
weeks during the screening ultrasonographic examination.^^
In a previous study by Shields, 274 fetuses had isolated choroid plexus
cysts on ultrasound with only 7 fetuses having abnormal karotypes.^* The risk o f
trisomy 18 in fetuses with an isolated choroid cyst noted on second trimester
ultrasound was determined to be 1.9%. At this time. Shields at el. suggested that
an isolated choroid cyst in a fetus with a normal maternal serum screen may not
need invasive testing.^*
Vintzileos et al. and Bahado-Singh et al. both conducted studies that
focused on determining the importance o f ultrasound and triple marker screen
used in combination to detect trisomy 21 risk. Bahado-Singh et al. used
ultrasonographic biometry and anatomic survey to obtain the best combination o f
biometry parameters for the detection o f Down's syndrome and other
chromosomal anomalies.^^ This study established values for nuchal thickness,
humerus length, femur length, and fetal anatomy which would elicit a statistically
significant percentage o f chromosome abnormality in a positive triple screen
population. With the use o f a combination o f ultrasonographic parameters in the
present study, fetuses at greatest risk for trisomy 21 and other significant
chromosomal abnormalities such as trisomy 18 among positive triple screen
pregnancies were identified. The researchers thus concluded that a normal
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ultrasonography result significantly reduces the risk o f any clinically significant
chromosomal defect/^ A previous study by Bahado-Singh et al. showed that the
chance o f finding Down’s syndrome in a triple-screen-positive pregnancy is
significantly reduced with a normal nuchal thickness and no fetal structural
abnormalities on ultrasonography.’ They also established that the risk from
amniocentesis significantly exceeds the risk o f finding Down syndrome in these
same fetuses with normal nuchal thickness and no fetal structural abnormalities.
Thus, a major benefit o f defining those triple-screen-positive pregnancies at low
risk for chromosomal abnormalities as noted in the present study is a potential
reduction o f performing genetic amniocentesis on such a population.’
In response to conflicting results o f prenatal ultrasonographic findings in
trisomy 21, Vintzileos et al. conducted a study to establish the average sensitivity
and specificity o f ultrasonographic markers in the second trimester o f pregnancy.'^
Based on these findings, the researchers were able to derive an adjusted risk for
trisomy 21 for both high- and low-risk populations.'^ The significance o f this data
is that second-trimester ultrasonography is an important key in adjusting the need
for genetic amniocentesis in women with abnormal triple serum biochemistry
results. These results allow for better selection o f candidates for genetic
amniocentesis and thus minimize amniocentesis-related fetal loss. Both studies
by Vintzileos et al. and Bahoado-Singh et al. validate the significance of
ultrasonographic biometry in combination with a positive triple serum screen in
detecting trisomy 21 prenatally.
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Amniocentesis
Amniocentesis was first known to be performed for genetic studies in the
1950’s; however, the first report that a fetal karyotype could be obtained from
cultured amniocytes for the purpose o f prenatal diagnosis was made by Steel and
Breg in 1966."^^' Then, in 1972, Hsu et al. reported one o f the first cases o f
trisomy 18 diagnosed prenatally with the use o f transabdominal amniocentesis.*’
This procedure was performed at 16.5 weeks gestation on a 40 year old women
secondary to her advanced maternal age. Chromosomal analysis, performed on
the amniotic fluid culture, indicated trisomy 18. Using prenatal amniocentesis and
pathologic examination, the researchers were able to conclude that trisomy 18
could be detected as early as twenty weeks gestation.”
With the heightened use o f amniocentesis, safety, as well as its effects on
the fetus and maternal outcome, was under debate. In 1971, the National Institute
o f Child Health and Human Development (NICHD) initiated the National
Registry for Amniocentesis to conduct a prospective study to investigate the
safety and accuracy o f mid-trimester amniocentesis.^* The study involved 1,040
subjects and 982 controls. The registry data focused on immediate complications
o f amniocentesis such as fetal loss at the time o f delivery, birth difficulties,
congenital abnormalities, and follow-up at one year o f age in order to note any
possible developmental problems. The overall fetal loss by the women undergoing
amniocentesis was 3.5% compared to 3.2% for the controls. There were no
significant findings for the infants in death rates, medical history, or physical
growth between the two groups at the one-year follow-up. Overall, the NICHD
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study group concluded that amniocentesis was a safe procedure; however, they
did not discount the potential risks that accompany the procedure even though the
data indicated the actual occurrence o f these risks to be small. The researchers
felt the results o f the study should help to advocate for the use o f amniocentesis in
older women with an increased risk for Down’s syndrome.^^
Since the time o f the report by the NICHD, several studies have followed
and have shown a small but significant procedure-related loss associated with
amniocentesis.^^"^ According to the bulletin constructed by the AGOG study
group on the safety and efficacy o f amniocentesis, the risk o f fetal loss associated
with amniocentesis was quoted as 1:200 procedures."*’ The procedure involves the
introduction o f an ultrasound guided 20- to 22-guage spinal needle through the
abdominal wall. The needle is then passed through the uterus and into the
amniotic sac. Approximately 20 to 30 ml o f amniotic fluid is extracted. The fluid
contains amniotic cells which are then cultured and karyotyped." Amniocentesis
is considered the gold standard for invasive prenatal diagnostic procedures;
however, it is essential that patients be informed o f the possible risks o f
amniocentesis including a procedural related loss o f 0.5 to 1.0%.*° "^^
Second trimester amniocentesis is currently offered on a routine basis to
women at risk for Down’s syndrome and other fetal a n e u p l o i d i e s . ^ T h e
population o f women at increased risk for fetal aneuploidies includes all women
age 35 years and older since the risk o f having a fetus with an autosomal trisomy
increases significantly after this age.'^^ Other indications for prenatal diagnosis
by amniocentesis include a positive maternal serum screen, history o f a child with
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a chromosomal abnormality, family history o f neural tube defects, and abnormal
results on fetal ultrasonography/^ Although less than 25% o f trisomy 21 infants
are bom to mothers over the age 35, the risk o f having an affected fetus in the
second trimester increases to 1 in 200.'^^* The risk o f procedure-related fetal loss
in this age group is considered to be the same or less than the risk o f having a
child with trisomy 21/° Because the birth incidence o f trisomy 18 is much lower
than that o f trisomy 21, the risk o f fetal loss secondary to amniocentesis may
actually be higher than the risk o f having a trisomy 18 infant.
The study by Spencer and colleagues demonstrates the need for further
research on performing routine amniocenteses on pregnant women who screen
positive for trisomy 18.‘* In this particular study, the birth incidence o f trisomy 21
was found to be 12.6/10,000 as compared to an incidence o f 1.3/10,000 for
trisomy 18. With the use o f maternal serum AFP and P-hCG for the prenatal
diagnosis o f trisomy 18 and trisomy 21, a detection rate o f 50% with a false
positive rate o f 1% and a detection rate o f 70% with a false positive rate of 5%
were obtained, respectively. Therefore, 8.8 cases o f trisomy 21 would be detected
for every 500 amniocenteses performed giving one case per 57 amniocenteses;
however, the detection rate for trisomy 18 would result in 154 women undergoing
amniocentesis to detect one case o f trisomy 18. This is significant in that this
would result in a loss o f just as many normal fetuses as abnormal fetuses detected.
Thus, it was concluded that the risk caused by follow-up amniocentesis was too
great for the number o f trisomy 18 fetuses detected at that time.'*

28

Routine second-trimester amniocentesis for women at an increased risk o f
trisomy 18 has not been found justifiable from a cost/benefit standpoint either.
This aspect o f routine amniocentesis was explored in a 1998 study by Vintileos et
al.^^ The researchers performed a cost/benefit analysis and cost effectiveness
determination o f three prenatal strategies for the detection o f trisomy 18. The
strategy of universal amniocentesis for all women at an increased risk o f trisomy
18 was found to be much more costly than the strategy o f no prenatal diagnostic
work-up o f at-risk patients, and the strategy o f genetic amniocentesis reserved for
at-risk patients with abnormal ultrasound results. The universal amniocentesis
approach would generate an annual cost o f approximately $12 million dollars and
40 fetal losses whereas the targeted genetic ultrasound approach would cost only
$5 million dollars annually with a fetal loss o f 8 as the result o f amniocentesis.^^
This study demonstrates that from a economic standpoint universal amniocentesis
is not a cost effective option for mothers at an increased risk for trisomy 18.
Summarv
The research and development o f screening programs are focused on
reducing the number o f women undergoing invasive procedures for definitive
diagnosis o f chromosomal abnormalities. Performing amniocenteses on all
women who screen positive on triple marker serum screen for chromosomal
abnormalities is both costly and carries the risk for fetal loss. This lends support
to further define a population at higher risk o f trisomy 18 in order to reduce the
number o f amniocenteses performed. When the risk o f the test is greater than the
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risk o f the abnormality, the patient needs guidelines to make informed decisions
regarding further evaluation.
Several studies have indicated the efficacy o f triple serum marker screen in
identifying trisomy 18.*’^' Many studies have also described abnormalities
associated with trisomy 18.‘‘'^ Furthermore, studies have demonstrated the ability
o f these abnormalities to be detected on ultrasound.^^^* While there were a few
ultrasounds that had no visible abnormalities but resulted in fetuses with trisomy
18, most o f those ultrasounds were performed before 17 weeks gestation.^^^^ Most
research published thus far has centered on altering the risk o f having a fetus
affected with trisomy 21 using non-invasive methods. These studies demonstrate
the significance o f using ultrasound and triple marker screen in combination to
determine trisomy 21 risk.'*'^’ The parameters and framework from these studies
can be extended to research involving trisomy 18. More specifically, the use of
ultrasound and triple screen in combination to identify a population at higher risk
for trisomy 18 must be researched.
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CHAPTER THREE
METHODOLOGY
Study Design
This study examined the risk o f trisomy 18 based upon triple marker
serum screen results and ultrasound findings. The project was a correlational
study o f the relationship between an abnormal triple marker screen, a normal
ultrasound, and the risk o f trisomy 18. A non-experimental design, specifically, a
non-concurrent cohort study, was conducted to obtain data. This was
accomplished through a retrospective and prospective chart review o f a cohort o f
pregnant women who had screened positive for trisomy 18. The retrospective
aspect was conducted between June 1, 1996 through July 31, 1998. The
remaining cases were followed from August 1, 1998 imtil September 30, 1999.
The starting date for the study was chosen because June 1996 was when trisomy
18 risk was first reported to the physician population. September 1999 was
chosen as a cut off date in order to allow adequate time to obtain pediatric
outcome prior to presentation o f this project in March o f 2000. The advantage of
using this particular study design was that it permitted a large population to be
studied within a specified amoimt o f time. Also, due to the low incidence o f
trisomy 18, access to the largest population possible was needed to obtain a
sufficient number o f trisomy 18 cases. The use o f a retrospective design does
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have the possibility o f missing data, loss to follow-up, and lack o f uniformity in
the recorded information.
The focus o f the study centered around the results o f the triple marker
screen and ultrasound as well as the outcome in terms o f presence or absence o f
trisomy 18. The triple marker serum screen results and ultrasound findings
constitute the independent variables. The triple marker screen consists o f testing
serum levels o f AFP, P-hCG, and unconjugated estriol. In a positive test for
trisomy 18, all o f the serum levels are lower than normal in the second trimester.®
Ultrasound was the other screening tool used to detect the presence o f trisomy 18.
Research has shown that there are specific abnormalities seen on ultrasoimd
commonly associated with trisomy 18. These sonographic findings include:
intrauterine growth retardation; congenital heart disease; single umbilical artery;
cystic hygromas; choroid plexus cysts; omphalocele; clenched hands; rocker
bottom feet; meningomyelocele; renal anomaly; and enlarged cistema magna.^®^^
The dependent variable in the study was the presence or absence o f trisomy 18.
Studv Site and Subiects
Study Site
The central site o f the study was conducted through Spectrum Health
Downtown campus in conjimction with W est Michigan Perinatology and
Spectrum Health Downtown Genetic and Cytogenetic departments. These
facilities serve the population o f West Michigan along with surrounding areas.
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The demographic profile o f this population ranges from urban to rural
encompassing various ethnic and socioeconomic backgrounds.
Subjects
Subjects were initially recruited by referral through their primary
physician for a triple marker serum screen based on their gestational age. All
pregnant women with fetuses between the gestational age of 15 to 22 weeks are
offered the triple marker serum screen. The study population included women
who were screened through Spectrum Health Downtown Campus Genetic
Screening Program. The cut-off levels at Spectrum Health Genetics lab for the
biochemical analytes in the serum marker screen consist of the following: AFP
0.70 MoM, estriol 0.55 MoM, and P-hCG 0.50. Using these levels, there is a 50%
detection rate with a 2% false positive rate. Based on the levels o f P-hCG, AFP,
and estriol, a risk for trisomy 18 was generated. The study sample included all
women with a calculated serum screen risk o f greater than 1:250 for trisomy 18.
These women then underwent ultrasound or ultrasound in combination with
amniocentesis. A computer-generated list o f all positive results for trisomy 18
was compiled. The risk calculation for trisomy 18 was instituted June 1, 1996.
The women included in this study had screened positive between this date and
September 30, 1999. Prior to June 1, 1996, the triple marker screen was being
done but was not evaluated for trisomy 18 risk calculation. Excluded from the
study were those with a normal risk based on recalculation with change in
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estimated date o f confinement (EDC), fetal demise at less than 20 weeks, and
termination at less than 20 weeks without amniocentesis.
Equipment and Instruments
This study was a chart review in which data were collected concerning
ultrasound findings and fetal outcome. No direct instrumentation was used during
the study. Ultrasoimd and amniocentesis were done prior to the chart review.
The technique o f ultrasound is widely used as a general, non-invasive
screening tool and it is considered to be a safe method for obtaining information
about the fetus and its environm ent/ Ultrasound biometry is now the gold
standard for assessing fetal growth. A number o f second-trimester ultrasound
findings have been found to be frequently associated with fetal aneuploidy
including; smaller biparietal diameter; shorter femur length and humerus length;
thickened nuchal fold; pyelectasis; increased bowel echogenicity; abnormal heart
anatomy and abnormal flexion o f the hands.^^ In trisomy 18, the most common
structural abnormalities present on ultrasound consist of: cardiac or abdominal
wall defects; central nervous system abnormalities; renal abnormalities; single
umbilical artery; structural anomalies o f the hands and feet; and intrauterine
growth retardation.^*'*’ The specificity and sensitivity o f the ultrasound depends
on a number o f factors including the quality o f screening equipment, the expertise
o f the ultrasonographer, and the specific abnormality being evaluated.
Amniocentesis for prenatal diagnosis is the most common invasive
procedure offered to pregnant women who have an increased risk o f chromosomal
aberration."* The procedure involves the introduction o f an ultrasound- guided
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needle through the uterus into the amniotic sac. A small amount o f amniotic fluid
is aspirated with the needle and then sent to a lab for genetic evaluation and
karyotyping.^’
Validity and Reliability o f Amniocentesis
In 1976, the diagnostic accuracy of mid-trimester amniocentesis was found
to be 99.4% by the NICHD National Registry for Amniocentesis Study Group
(NICHD).

Since the early 1970’s, the accuracy and reliability o f amniocentesis

has been well established and is considered the “gold standard" for the diagnosis
of chromosomal abnormalities.'® "
Procedure
The data was primarily collected through chart review o f those women
who screened positive for trisomy 18 using triple marker screen through Spectrum
Health Downtown Campus Genetic Screening Program. A list o f the women with
abnormal triple screens was generated. The data needed for the study were
retrieved from individual patient charts. A majority o f the charts were available
from the W est Michigan Perinatology Office. The remaining charts were
obtained through mailings and telephone calls to the woman’s primary care
provider at the time o f pregnancy. Review consisted o f maternal demographic
data, triple screen results, ultrasound evaluation, amniocentesis rates and results,
and outcome assessment based on amniocentesis results, office documentation,
review o f birth records, or telephone contact with mother.
The data was collected by the three authors o f the study, all o f whom are
physician assistant students, and also Dr. Dawn De Witt. All data collectors were
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consistent in finding and recording the information from the individual charts. In
cases in which charts could not be reviewed directly, a standard form was sent to
the practitioners office requesting the specific information needed. Upon
receiving the completed form, the information was transcribed in a manner
consistent with the data directly obtained. Data collection began September 1998
and continued through November 1999.
Because o f the design o f the study, there exist missing data and incomplete
data. An exhaustive search for data was performed and all attempts to locate
missing data was carried out. For charts outside o f the West Michigan
Perinatology office, a mailing was sent requesting information from practitioners
on subjects in the study. Follow-up phone calls were made to those offices which
had not responded to the initial request by mail. Attempts to further complete
pediatric follow-up was carried out through phone calls to the mother and review
o f Spectrum Health’s labor and delivery log book.
There were no direct risks to the individual patients since this study was a
chart review. Maintaining patient confidentiality was the only concern for this
type o f study. Confidentiality was preserved by sequential assignment of
numbers to all patients so that names and identifying information were protected.
Throughout the study, patients were only identified and referred to by their
assigned number. Individual informed consent was not necessary due to
preserved confidentiality and absence o f direct patient contact.
T h i s s t u d y w a s d o n e i n c o n j u n c t i o n w i t h D a w n D e W itt. M D , c h i e f O b s t e t r i c s a n d
G y n e c o lo g y r e s id e n t.
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CHAPTER FOUR
RESULTS/DATA ANALYSIS
Study Population
A total o f 13,618 maternal subjects were screened for fetal trisomy 18
from June 1996 to September 1999. O f the total number screened, 158 (1.2%)
had a positive result. Ten were excluded from the study due to fetal demise or
termination at less than 20 weeks gestation. Another 8 were excluded with
recalculation o f estimated date of confinement (EDC) and 1 subject was removed
due to her non-pregnant status. Ultrasoimd data was not available on 19 o f the
139 identified making the total number in our study population 120 (86.3%).
Techniques o f Data Analysis
The study population was divided into two groups: normal ultrasound and
abnormal ultrasound. The two groups were compared demographically to initially
rule out any biases since the study was non-randomized. A comparison analysis
o f the collected data was performed using Pearson Chi-Square, Mann Whitney U,
or Fischer Exact where appropriate. Significance was defined as p< 0.05.
Comparison o f normal ultrasound to abnormal ultrasound was based on the
following maternal demographic components: age, advanced maternal age (age >
35 years), diabetes, weight, estimated gestational age (EGA) at ultrasound, EGA
at triple screen, and triple screen risk. Assessment o f neonatal data included the
percentage undergoing amniocentesis, the percentage o f aneuploidies, and the
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percentage o f trisomy 18. Results o f this data are shown in Table 1 and Table 2,
respectively (See Appendix A). Data analysis was provided by Justine Ritchie,
Assistant Professor o f Mathematics and Statistics at Grand Valley State
University.
Characteristics o f Subiects
Differences in the maternal data were not significant in any o f the
categories except weight distribution. The mean weight for the normal ultrasound
group was 158.1 pounds as compared to 143.1 pound for the abnormal ultrasound
group (p <0.03). The results o f the neonatal data demonstrate statistically
significant differences between the normal and abnormal ultrasound groups. The
total number o f aneuploidies detected in the study was 10. The percentage o f
aneuploidy was 38.1% in the abnormal group and 2.5% in the normal group.
Among the 8 aneuploidies with abnormal ultrasounds, there were 4 that were
found to be trisomy 18. The other aneuploidies visualized on ultrasound consisted
o f 1 case o f trisomy 16, 46 XX 9ph, 46 XX 4p-, and 1 triploidy. The two
aneuploidies with normal ultrasounds were karyotyped as 46XX with an inversion
o f 1 Iq and 47XYY. No cases o f trisomy 18 were found in the normal ultrasound
group, where as all 4 cases o f trisomy 18 were found in the abnormal ultrasound
group (p <0.001).
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CHAPTER FIVE
DISCUSSION AND IMPLICATIONS
Discussion of Findings
Analysis o f maternal data demonstrates that the only characteristic
significantly different between the two identified groups is that o f weight
distribution. One may argue that, in theory, ultrasound is more difficult to perform
and evaluate on larger women due to poor visualization o f fetal anatomy. In our
study, however, no cases o f trisomy 18 were missed on ultrasound. According to
the results of the neonatal data, a higher percentage o f amniocentesis procedures
were performed in the abnormal compared to the normal set. This is an expected
outcome in that many o f those having an abnormal test typically pursue further
evaluation. A majority o f the aneuploidies had detectable abnormalities
visualized on ultrasound. All o f the trisomy 18 cases had abnormalities that were
detected on ultrasound. Four other aneuploidies were identified on ultrasound.
These consisted o f 1 case o f trisomy 16,1 case o f female with 46 chromosomes
with an abnormality o f the heterochromatin on the short arm o f chromosome 9, 1
case o f a female with 46 chromosomes with a deletion on the short arm of
chromosme 4, and 1 case o f triploidy. Two aneuploidies, 46XX with an inversion
o f chromosome 1 Iq and 47XYY, did not present with abnormalities on
ultrasoimd. Both o f these are considered minor chromosome abnormalities and
are not expected to be detected on ultrasound.
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Application o f Practice
The results o f our study potentially will affect the genetic counseling o f
women at high risk for trisomy 18 as defined by triple marker screen. We hope to
provide those women who screen positive for trisomy 18, yet have normal
ultrasound results, the ability to make a more informed decision about
amniocentesis based on their adjusted risk. Although amniocentesis is a definitive
test for the determination o f chromosomal abnormalities, it is not without risk. In
theory, the application o f our data in a clinical setting would lead to a reduction in
the number o f amniocenteses performed on women with normal fetal ultrasounds.
Limitations and Recommendations
Limitations o f this study include the size o f our sample population and a
limited number of trisomy 18 cases within this population. Complete data was
unable to be recovered as this information was contained in patient charts located
in various offices throughout Michigan. Due to the fact that this study was non
randomized, we are unable to extend our findings to the general population.
Before the results o f this study can be implemented into clinical practice,
further studies targeting a larger population will lend itself to the reliability o f this
study. Furthermore, a prospective study following a population at increased risk
for trisomy 18 based on triple marker screen will minimize amount o f incomplete
data. Additional studies are needed that focus on the detection o f trisomy 18
using non-invasive procedures.
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Conclusions
The purpose o f this study was to determine whether the risk o f trisomy 18
in women who screened positive for trisomy 18 yet had normal ultrasound results
was less than the procedure-related risk o f amniocentesis. In other words, is the
risk o f amniocentesis-related loss greater than the risk o f having a trisomy 18
fetus? We found in our study population that the presence o f normal ultrasound
findings is not associated with an increased risk o f trisomy 18. The analyzed data
showed that women with a positive triple screen but a normal ultrasound were at
significantly less risk o f actually having a trisomy 18 fetus than the women with
abnormal ultrasounds. Furthermore, abnormal ultrasound findings are
significantly associated with an increased risk o f trisomy 18 and other
aneuploidies. All cases o f trisomy 18 in this study population had an abnormal
ultrasound. Therefore, amniocentesis for all positive triple screens in this study
population is not justified for the identification o f affected infants.
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APPENDIX A
Data Tables

Table 1
Maternai Demographic Data: Comparison o f patients with
positive triple marker serum screen for trisomy 18

Age* (years)

Normal
Ultrasound
Group
31.0

Abnormal
Ultrasound
Group
29.7

NS

AMA^ (%)

34.7

22.7

NS

Weight^ (lbs)

158.1

143.1

p <0.03

DM^ (%)

2.0

4.5

NS

EG A atTS*
(wks)
EGA at US'*
(wks)
TS Risk^

17.6

17.9

NS

20.6

19.8

NS

1:130

1:103

NS

Demographic
Data

* Statistical significance defined as p <0.05
1.
2.
3.
4.
5.
6.
7.

Mean age o f subjects in years
% o f subjects with advanced maternal age (age >35)
Mean weight of subjects in pounds
% o f subjects with diabetes mellitus
Mean estimated gestational age at triple screen
Mean estimated gestational age at ultrasound
Mean calculated triple screen risk ratio

Statistical
Significance*

Table 2
Neonatal Data: Comparison o f fetal data from pregnant women
with a positive triple marker serum screen for trisomy 18

Amniocentesis* (%)

Normal
Ultrasound
Group
31.9

Abnormal
Ultrasound
Group
68.2

P <0.002

Trisomy 18"* (%)

0

19

P <0.001

Aneuploidy^ (%)

2.5»*

38.1

P <0.001

Demographic Data

Statistical
Significance*

*Statistical significance is defined as p <0.05
**2.5%(n=2) o f the fetuses in the nonnal ultrasound group had some type of
aneuploidy. However, these aneuploidies were not significant as fetal outcome is
expected to be good. Furthermore, no abnormalities from these two aneuploidies
are expected to be detected on ultrasound.
1. % o f subjects who had amniocentesis performed
2. % o f fetuses actually having trisomy 18
3. % o f fetuses with aneuploidy as determined by amniocentesis

APPENDIX B
Data Collection Forms

F^atiant

MR Numocr"

Nam#

O alaShM l

PatiMt Agt Weight Race Parity Dlal>etee EGAatTS DateTS TSRIek B-HCG AFP Eetifol EGA at US Date US

O tIaShM l

Echog#mlc bowel

Abd. wall
defect

Other abnl.

BPD AC

FL

RL

Amnlocenteels

Résulta

Pediatric
follow up
(If no amnio)

OatoShM l

Nuchal
Renal cardiac defect type cardiac defect Umbe < 5% Choroid SUA Abnl hands Abnl feet
thicknest pyeleclatis
plexus
>6mm

>4mm

cyst

APPENDIX C
Proposal and Project Approval Forms

BU TTERW O RTH HO SPITA L RESEARCH AND HUMAN R IG H T S
ASSURANCE FORM
Instructions to Research Investigator: Complete Section I and n with signature.
Complete either A, B, C or D as appropriate to your project. Investigators are referred
to the Research Guidebook and the enclosed Butterworth Hospital policies. Consultants
please refer to E. Please return this form to the Butterworth Hospital Research Office
using the enclosed envelope.
SECTION I:
Investigator:
Address: / 0 3 2 4

A M va.11***^
iCtwV * 1_

Telephone:
(616) 6 ft^ ~ 5 (p O S __________
Co-Investigator: Cu r f i s
fnok ^
Titie o f Protocol: DlVvD.sou-.vr*
lytC.l'tCLSK*
oC"
Other institutions involved:
tX Yes
(ex: hospital, school)
If yes, name o f other institution: - A V & P —

No

Ots “Tr^pVx St.Vv>."^
a»\»4 ^ 1 -9 (

____________

_A. Research Presenting Possible Risk to Patients:
e.g. drug and medical device trials, surgical and other invasive procedures,
studies involving randomization, placebo controls, including Phase IV, etc.
If you have not done so previously, PLEASE SUBMIT:
One copy o f the complete protocol, including budget, data forms,
consent form, bibliography. If not a Butterworth Hospital staff member,
please include CV and institutional letter o f approval.
B. Research Presenting Minimal Risk to Subjects:
In order for your study to be categorized as a "minimal risk" project it must
fall into one o r more of the following areas: PLEASE INDICATE THE
CATEGORY.

1. ColIecdoR o f hair and nail clippings, excreta and external secretions,
uncannulaced saliva, placenta removed at delivery, amnxodc fluid at time o f
rupture of the membrane, deciduous teeth, and perm anent teeth if patient care
indicates a need for extraction. Collection o f dental plaque and calculus done
in a non-invasive manner perform ed according to standard prophylactic
techniques.
2. Collection o f blood sample by venipuncture, in amounts not exceeding 450
milliliters in an eight (8) week period, and no more often than twice a week,
from subjects over 18 years o f age, in gcxxi health, and n o t pregnane
3. Recorc&ng of data from subjects 18 years o r older using non-invasive
procedures routinely employed in clinical practice (e.g ., weighing, testing
sensory acuity, electrocardiography, electroencephalography, thermography not x-rays or microwaves).
4. Moderate exercise by healthy volunteers.
5. Voice recordings m ade for research purposes.
6. Research on Behavior:
perception smdies;
cognition;
game
dieory;
test development, where the investigator does not manipulate
subjects' behavior and the research will n o t involve stress to subjects.

y

C. R eseardi Presenting N o Risk to Subject:
In order for your research to be considered as a "no risk" study, it m ust 611 into one or
m ore o f the following categories. PLEASE INDICATE W HICH A R£A (S) APPLY:
1. Use o f educational tests for which there is no subject identiQring data.
2. Researdx involving collection o r study o f charts, ^ e c im e n s, or methcal
records for which there will be no subject identifying data.
3. Research involving questionnaire, surveys, and/or interviews. Subjects
cannot be identified from data; subjects' response, if Imown, will not place

them ac risk; research does aoc deal with sensitive aspects o f subjects'
behavior (e .g ., illegal conduct, drug or alcohol use, sexual behavior). All
conditions m ust be met.
D. Kon-clinical studies, includes teaching and laboratory protocols and those listed in 21 CRF,
subpart A, Sec. 5 8 .3 .
E. Consultant. Reason fo r consultation:________________________________________________
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ALL INVESTIGATORS M U ST SIG N TH E FOLLOWING STATEM ENT O F ASSURANCE:
M y signature intficates my research project (s) / activiQr is prepared an d will be conducted, in
accordance with federal and instxtutional policies pertaining to resea rd i. Those federal policies are as
outlined by the FDA, ÜSDA an d H H S. I have read and understand Butterworth Hospital’s policies
concerning research, which include those on federal regolaiioas, m isconduct, conflict o f interest and
authorsfaç and I agree:
1. To obtain infenned ctxisent for subjects who a re to participate in fois project.
2. To pronçtly report to the Research and Human Rights Com m ittee, in writing, any changes
made in the protocol to protect foe life o f subjects. T his includes but is not limined to tide
and/or investigattx changes.
3. To promptly report to the R esearch and Human Rights Com m ittee, in w riting, any
unanticipated o r adverse effects, including study patient deaths, which become apparent
during foe course o r a s a result o f experimentation and th e actions taken as a result .
4. To obtain prior approval foom the committee before am ending o r altering the scope o f the
project or implementing dxanges in the approved consent form .

5. T o coopecaxe with m em bers o f che commioee charged with the continuing review o f this
project6. T o maintain documentatioa o f consent forms and progress reports as required by federal and
institutional policy.
7. T o maintain the confidentiality o f this information at all tim es. Any unauthorized disclosure
to a person o r company is considered a breech o f confidentialiy, and as such a violation o f
hospital policies, including the misconduct policy. It m ay also be a reason fo r legal action
to be taken against you.
8. I f doing consulting w ork relative to any research activiry. I agree to follow and adhere to the
policies as cited.
Signatureq_

Date:
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April 14, 1999

Samantha Mullln, Loralee Davison, Molly Kerr
10318 42"‘‘ Ave.#12
Allendale, MI 49401

Dear Samantha:

Your proposed project entitled "NeonaUU Oulcoine Based on Triple Serum Screening
and Ultrasound Findings in Pregnancies with an Increased Risk o f Trisomy 18” has
been reviewed. It has been approved as a study which is exempt from the regulations
by section 46.101 of the Federal Register 46(16):8336, January 26, 1981.

Sincerely,

Paul Huizenga, Chair
Human Research Review Committee

M EDICAL RECORDS CONFIDENTIALLY STATEMENT

Hospital/Clinical Facility places great
imp6rtance in the confidentiality o f medical records. Use o f the medical records for
research o r learning experience is permitted, provided the researcher or student realizes
his/her role in responsibility in protecting the confidentiality o f personally identifiable
information. Misuse o f infixmation collected could result in personal liability and the
implementation o f punitive action.
I acknowledge that I have read the above statement and take the responsibility fix proper
and limited use o f the confidential information in my research project or educational
activity.

Signature

Date

Research ProjèctÆducational Activity

Instructors Signature

